Anacor attracts big pharma investment
This article was originally published in Scrip
Anacor Pharmaceuticals has raised $50 million after two major pharmaceutical firms joined other investors in an equity financing. GlaxoSmithKline and Schering-Plough joined a host of venture capitalists to advance Anacor's product development. GSK and Schering-Plough will together own less than 20% of Anacor and their investment fulfils obligations related to ongoing collaborations with the company. The proceeds will allow Anacor to develop its five clinical programmes and identify new compounds derived from its boron chemistry platform. Anacor's lead compound is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. The candidate is licensed to Schering-Plough for all indications.
You may also be interested in...
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.